The venerable Financial Times this morning revealed that US pharma giant Pfizer is in the advanced stages of buying Biohaven, a US-listed firm that has been working on treatments for migraines. Below is the link:
https://www.ft.com/content/ea9bb9bc-b5ec-4278-ab42-1f5f14a1a76f..
Typical!
Betaville was just in the process of liasing with one of the institutional data providers for the deals numbers for this quarter to prove my own theory that the volume of announced public transactions had fallen off cliff for this period compared to previous years when: boom - Pfizer and GlaxoSmithKline announce a £10billion merger of their respective consumer healthcare businesses. Below is a link to the news:..
Shire is closing in on a multi-billion dollar takeover of US-listed Radius Health, a company that specialises in developing treatments for people with osteoporosis.
To be fair, rumours about Shire's interest in Radius are not particularly new. Talk of Shire pouncing on Radius, which currently has a market capitalisation of $2.2 billion, has been doing the rounds over the last twelve months...
Hacks at the FT last night landed a rather good scoop about Pfizer winning the long running Medivation auction with a $14 billion takeover bid. Here is the link:
http://www.ft.com/cms/s/0/0b556924-67e5-11e6-a0b1-d87a9fea034f.html#axzz4Hzh24lte..